Collaborative multidisciplinary workshop report: Progress toward a Chlamydia pneumoniae vaccine

Journal of Infectious Diseases

Volumn 181, Issue 6 SUPPL. 3, 2000, Pages

  Murdin, Andrew D ^k   Gellin, Bruce ^c   Brunham, Robert C ^a   Campbell, Lee Ann ^d   Christiansen, Gunna ^b   Deal, Carolyn D ^e   Jenson, Hal B ^f   Metcalf, Benjamin ^g   Sankaran, Banu ^h   Stephens, Richard S ⁱ   Wilfert, Cathy ^j  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b AARHUS UNIVERSITY   (Denmark)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

^e CENTER FOR BIOLOGICS EVALUATION AND RESEARCH   (United States)

^f UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^g Molecular Biology and Genetics   (United States)

^h PFIZER INC   (United States)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

^k Aventis Pasteur   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL VACCINE;

ATHEROSCLEROSIS; BRONCHITIS; CARDIOVASCULAR DISEASE; CHLAMYDOPHILA PNEUMONIAE; CONFERENCE PAPER; IMMUNE RESPONSE; LIPID METABOLISM; PRIORITY JOURNAL; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 0034120060     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315601     Document Type: Conference Paper

References (13)

1. 1. Grayston JT. Background and current knowledge of Chlamydia pneumoniae and atherosclerosis. J Infect Dis 2000; 181(suppl 31):S402-10.
2. 2. Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia: WB Saunders, 1999.
3. 3. Parkman PD, Hardegree MC. Regulation and testing of vaccines. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia: WB Saunders, 1999:1131-43.
4. 4. Ebbert GB, Mascolo ED, Six HR. Overview of vaccine manufacturing and quality assurance. In: Plotkin SA, Orenstein WA, eds. Vaccines. 3rd ed. Philadelphia: WB Saunders, 1999:40-6.
5. 5. Paoletti LC, McInnes PM, eds. Vaccines: from concept to clinic: a guide to the development and clinical testing of vaccines for human use. Boca Raton, FL: CRC Press, 1998.
6. 6. Centers for Disease Control and Prevention. Poliomyelitis prevention in the United States: introduction of a sequential schedule of inactivated poliovirus vaccine followed by oral poliovirus vaccine. MMWR Morb Mortal Wkly Rep 1997; 46(RR-3):1-25.
7. 7. American Academy of Pediatrics, Committee on Infectious Diseases. Poliomyelitis prevention: revised recommendations for use of inactivated and live oral poliovirus vaccine. Pediatrics 1999; 103:171-2.
8. 8. Centers for Disease Control and Prevention. Recommendations of the Advisory Committee on Immunization Practices: revised recommendations for routine poliomyelitis vaccination. MMWR Morb Mortal Wkly Rep 1999; 48:590.
9. 9. Centers for Disease Control and Prevention. Intussusception among recipients of rotavirus vaccine-United States, 1998-1999. MMWR Morb Mortal Wkly Rep 1999; 48:577-81.
10. 10. American Academy of Pediatrics, Committee on Infectious Disease. Possible association of intussusception with rotavirus vaccine. Pediatrics 1999; 104: 575.
11. 11. Murdin AD, Dunn P, Sodoyer R, et al. Use of a mouse lung challenge model to identify antigens protective against Chlamydia pneumoniae lung infection. J Infect Dis 2000; 181(suppl 31):S544-51.
12. 12. Chang MH, Chen CJ, Lai MS, et al. Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. N Engl J Med 1997; 336:1855-9.
13. 13. Ward ME. The immunobiology and immunopathology of chlamydial infections. APMIS 1995; 103:769-96.